The BSRBR-RA at 15 Years

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2016 Mar 26

PMID 27012687

Citations 7

Authors

Elaine M Dennison

Jon Packham

Kimme Hyrich

Affiliations

Soon will be listed here.

Citing Articles

Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions.

Seo M, Debray T, Ruffieux Y, Gsteiger S, Bujkiewicz S, Finckh A Stat Methods Med Res. 2022; 31(7):1355-1373.

PMID: 35469504 PMC: 9251754. DOI: 10.1177/09622802221090759.

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.

Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S BMJ Open. 2021; 11(11):e050176.

PMID: 34824113 PMC: 8627413. DOI: 10.1136/bmjopen-2021-050176.

The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register.

Jones G, Macfarlane G, Forrest Keenan K, McNamee P, Neilson A, Siebert S BMC Rheumatol. 2021; 5(1):19.

PMID: 33993880 PMC: 8126428. DOI: 10.1186/s41927-021-00189-0.

Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.

Tikhonova I, Yang H, Bello S, Salmon A, Robinson S, Hemami M Health Technol Assess. 2021; 25(8):1-248.

PMID: 33555998 PMC: 7898084. DOI: 10.3310/hta25080.

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.

Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C Clin Med (Lond). 2020; 20(3):256-261.

PMID: 32371418 PMC: 7354033. DOI: 10.7861/clinmed.2020-0149.

References

Hyrich K, Watson K, Silman A, Symmons D . Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006; 45(12):1558-65. DOI: 10.1093/rheumatology/kel149. View

Mercer L, Green A, Galloway J, Davies R, Lunt M, Dixon W . The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012; 71(6):869-74. PMC: 3371225. DOI: 10.1136/annrheumdis-2011-200622. View

Hyrich K, Lunt M, Dixon W, Watson K, Symmons D . Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford). 2008; 47(7):1000-5. PMC: 2430221. DOI: 10.1093/rheumatology/ken127. View

Hyrich K, Deighton C, Watson K, Symmons D, Lunt M . Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 2009; 48(10):1323-7. PMC: 2744336. DOI: 10.1093/rheumatology/kep242. View

Galloway J, Hyrich K, Mercer L, Dixon W, Fu B, Ustianowski A . Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with.... Rheumatology (Oxford). 2010; 50(1):124-31. PMC: 3105607. DOI: 10.1093/rheumatology/keq242. View